Ipilimumab-induced Ocular and Orbital Inflammation - A Case Series and Review of the Literature

Ocular Immunology and Inflammation

Volumn 24, Issue 2, 2016, Pages 140-146

  Papavasileiou, Evangelia ^a   Prasad, Sashank ^b   Freitag, Suzanne K ^a   Sobrin, Lucia ^a   Lobo, Ann Marie ^a  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Autoimmune adverse events; CTLA 4 inhibitors; eye and orbit complications; ipilimumab; melanoma

Indexed keywords

ACICLOVIR; BEVACIZUMAB; CORTICOSTEROID; ERYTHROMYCIN; HYDROCORTISONE; IPILIMUMAB; METHYLPREDNISOLONE; PREDNISOLONE ACETATE; PREDNISONE; STEROID; ANTINEOPLASTIC AGENT; CTLA4 PROTEIN, HUMAN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GLUCOCORTICOID; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; AUTOIMMUNE HEPATITIS; AUTOIMMUNE PANCREATITIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CHEMOSIS; CLINICAL ARTICLE; CLINICAL FEATURE; COLITIS; CORTICOSTEROID THERAPY; DIPLOPIA; DRUG WITHDRAWAL; EXOPHTHALMOS; EYE INFLAMMATION; EYE PAIN; EYELID EDEMA; FEMALE; HUMAN; HYPOPHYSITIS; KERATITIS; MALE; METASTATIC MELANOMA; MIDDLE AGED; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OPHTHALMOPLEGIA; ORBIT INFLAMMATION; RETROSPECTIVE STUDY; SYSTEMIC THERAPY; THYROIDITIS; TOPICAL TREATMENT; UVEITIS; CASE REPORT; CHEMICALLY INDUCED; CORNEAL ULCER; IMMUNOLOGY; ORBITAL CELLULITIS; X-RAY COMPUTED TOMOGRAPHY;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CORNEAL ULCER; CTLA-4 ANTIGEN; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; ORBITAL CELLULITIS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; UVEITIS;

EID: 84940182635     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.3109/09273948.2014.1001858     Document Type: Article

References (22)

1. Della Vittoria Scarpati G, Fusciello C, Perri F, et al. Ipilimumab in the treatment of metastatic melanoma: management of adverse events. Onco Targets Ther. 2014;7: 203-209.
2. Tarhini A. Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: The underlying mechanisms and clinical management. Scientifica (Cairo). 2013:857519. 1-19.
3. Weber JS, O'Day S, Urba W, et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol. 2008;26:5950-5956.
4. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol. 2005; 23:6043-6053.
5. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-723.
6. National Cancer Institute (NCI). Common Terminology Criteria for Adverse Events 3.0. Bethesda, MD: NCI; 2006. ctep.cancer.gov/protocolDevelopment/electronic-applications/docs/ctcaev3.pdf [last accessed 30 Oct 2014].
7. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by CTLA-4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA. 2003; 100:8372-8377.
8. Trinh VA, Hagen B. Ipilimumab for advanced melanoma: A pharmacologic perspective. J Oncol Pharm Pract. 2013;19: 195-201.
9. Lecouflet M, Verschoore M, Giard C, et al. Orbital myositis associated with ipilimumab. Ann Dermatol Venereol. 2013; 140:448-451.
10. Modjtahedi BS, Maibach H, Park S. Multifocal bilateral choroidal neovascularization in a patient on ipilimumab for metastatic melanoma. Cutan Ocul Toxicol. 2013;32: 341-343.
11. Borodic G, Hinkle DM, Cia Y. Drug-induced Graves disease from CTLA-4 receptor suppression. Ophthal Plast Reconstr Surg. 2011;27:e87-e88.
12. Min L, Vaidya A, Becker C. Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. Eur J Endocrinol. 2011;164:303-307.
13. Henderson AD, Thomas DA. A case report of orbital inflammatory syndrome secondary to ipilimumab. Ophthal Plast Reconstr Surg. 2014:e1-e3. [Epub ahead of print].
14. Sanderson K, Scotland R, Lee P, et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. Clin Oncol. 2005;23:741-750.
15. Voskens C, Cavallaro A, Erdmann M, et al. Anti-cytotoxic T-cell lymphocyte antigen-4-induced regression of spinal cord metastases in association with renal failure, atypical pneumonia, vision loss, and hearing loss. J Clin Oncol. 2012;30:e356-e357.
16. Robinson MR, Chan CC, Yang JC, et al. Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: A new cause of uveitis. J Immunother. 2004;27:478-479.
17. Voskens CJ, Goldinger SM, Loquai C, et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One. 2013;8:e53745.
18. Audemard A, de Raucourt S, Miocque S, et al. Melanomaassociated retinopathy treated with ipilimumab therapy. Dermatology. 2013;227:146-149.
19. Goldstein BL, Gedmintas L, Todd DJ. Drug-associated polymyalgia rheumatica/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of ctla-4. Arthritis Rheumatol. 2014;66:768-769.
20. Liao B, Shroff S, Kamiya-Matsuoka C, Tummala S. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol. 2014;16: 589-593.
21. Wong RK, Lee JK, Huang JJ. Bilateral drug (ipilimumab)-induced vitritis, choroiditis, and serous retinal detachments suggestive of Vogt-Koyanagi-Harada syndrome. Retinal Cases Brief Rep. 2012;6:423-426.
22. Nallapaneni NN, Mourya R, Bhatt VR, et al. Ipilimumabinduced hypophysitis and uveitis in a patient with metastatic melanoma and a history of ipilimumab-induced skin rash. J Natl Compr Canc Netw. 2014;12:1077-1081.